Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Frank, Struyf"'
Autor:
Nicolas Folschweiller, Carline Vanden Abeele, Laurence Chu, Pierre Van Damme, Adolfo García-Sastre, Florian Krammer, Raffael Nachbagauer, Peter Palese, Alicia Solórzano, Dan Bi, Marie-Pierre David, Damien Friel, Bruce L Innis, Juliane Koch, Corey P Mallett, Ronan Nicolas Rouxel, Bruno Salaun, Valerie Vantomme, Céline Verheust, Frank Struyf
Publikováno v:
The lancet infectious diseases
Background One strategy to develop a universal influenza virus vaccine is to redirect the immune system to the highly conserved haemagglutinin stalk domain by sequentially administering vaccines expressing chimeric (c) haemagglutinins with a conserve
Autor:
Silvia Damaso, Tiina Eriksson, Matti Lehtinen, Dan Bi, Dan Apter, Julia Zima, Mari Hokkanen, Frank Struyf, Gary Dubin, Maaria Soila
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
This manuscript discloses end-of-study safety data of a community-randomized controlled trial in Finland (NCT00534638), assessing the effectiveness of two vaccination strategies (gender-neutral versus females only) using the AS04-adjuvanted human pap
Autor:
Tino F. Schwarz, Sylviane Poncelet, Li-Min Huang, Lan Lin, Naveen Karkada, Alejandra Valencia, Falko Panzer, Nicolas Folschweiller, Gary Dubin, Frank Struyf, Cheng-Hsun Chiu, Annabelle Decreux
Publikováno v:
Human Vaccines & Immunotherapeutics
This study assessed long-term immunogenicity and safety following 3 doses of AS04-adjuvanted human papillomavirus (HPV)-16/18 L1 virus-like particle (VLP) vaccine in females 10–14 years old. Girls included in the immunogenicity subset in the primar
Autor:
Ying Hong, Haiwen Tang, Fengcai Zhu, Shang-Ying Hu, Qin-Jing Pan, Cheng-Fu Zhang, Yuemei Hu, Xiaoping Yang, Xiaoqian Xu, Feng Chen, Fang-Hui Zhao, Dan Bi, Jia-Xi Yu, Shuang Zhao, Wen-hua Zhang, Jiahong Zhu, Yejiang Zhu, Xun Zhang, Frank Struyf, Naveen Karkada
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Human papillomavirus (HPV) vaccines are efficacious against HPV infections and associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) against oncogenic, high-risk HPV (HR-HPV) types in women infected with any other HR-H
Autor:
Mark Schiffman, Allan Hildesheim, Frank Struyf, Matti Lehtinen, Aimée R. Kreimer, Paula N. Gonzalez, Naveen Karkada, Carolina Porras, Wim Quint, John T. Schiller, Joseph E. Tota, Cosette M. Wheeler, Martin Ryser, John Schussler, Nicolas Folschweiller, Joshua N. Sampson, Ana Cecilia Rodriguez, Rolando Herrero
Publikováno v:
J Infect Dis
Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or higher i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::933100ecc1d04e70bdb2f618f4b1a38c
https://europepmc.org/articles/PMC8248553/
https://europepmc.org/articles/PMC8248553/
Autor:
Marjan Hezareh, Nicolas Folschweiller, Lars Rombo, Bee Wah Lee, Stéphanie De Simoni, Helen M. L. Oh, Franck Thollot, Ngiap Chuan Tan, Anthony P. Y. Liu, Fong Seng Lim, Roman Rouzier, Frank Struyf, Florence Thomas, P.V. Suryakiran, Ting Fan Leung
Publikováno v:
Vaccine. 36:98-106
This observer-blind study (clinicaltrials.gov NCT01462357) compared the immunogenicity and safety of two doses (2D) of the HPV-16/18 AS04-adjuvanted vaccine (2D of AS04-HPV-16/18) vs. two or three doses of the 4vHPV vaccine [2D or 3D of 4vHPV] in 107
Autor:
Mark Schiffman, Wim Quint, Rolando Herrero, Ana Cecilia Rodriguez, Carolina Porras, Cosette M. Wheeler, Aimée R. Kreimer, Naveen Karkada, Joseph E. Tota, Patricia Study, John Schussler, John T. Schiller, Joshua N. Sampson, Costa Rica Vaccine Trial, Martin Ryser, Frank Struyf, Allan Hildesheim, Paula N. Gonzalez, Nicolas Folschweiller
Publikováno v:
J Natl Cancer Inst
Background The AS04-adjuvanted HPV16/18 (AS04-HPV16/18) vaccine provides excellent protection against targeted human papillomavirus (HPV) types and a variable degree of cross-protection against others, including types 6/11/31/33/45. High efficacy aga
Autor:
Tino F. Schwarz, Paolo Durando, Marc Dionne, Khuanchai Supparatpinyo, Philippe Moris, Peter Hillemanns, Sylviane Poncelet, Klaus Peters, Brian Ramjattan, Frank Struyf, Michel Janssens, Murdo Ferguson, Shelly A. McNeil, Annabelle Decreux, Pemmaraju V Suryakirian, Ulrich Behre, Linda Ferguson, Susanna Esposito, Nicolas Folschweiller
Publikováno v:
The Journal of Infectious Diseases
This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9–14 years or following 3 doses in women aged 15–2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::115353feaeba807fb121bc70df36c880
http://hdl.handle.net/11567/957678
http://hdl.handle.net/11567/957678
Autor:
Ryo Konno, Newton De Carvalho, Cecilia Roteli-Martins, Nansa Burlet, Barbara Romanowski, S. Rachel Skinner, Attila Mihalyi, Frank Struyf, Jorma Paavonen, Dan Apter, Diane M. Harper
Publikováno v:
Expert Review of Vaccines. 15:367-387
Vaccines are available against human papillomavirus (HPV), the causal agent of cervical and other cancers. Efficacy data from the HPV-16/18 AS04-adjuvanted vaccine clinical trial program were reviewed. Six randomized, controlled phase II/III trials e
Autor:
Peter Hillemanns, Klaus Peters, Karin Schulze, Linda Ferguson, Marc Dionne, Ulrich Behre, P.V. Suryakiran, Tino F. Schwarz, Barbara Romanowski, Frank Struyf, Florence Thomas
Publikováno v:
Human Vaccines & Immunotherapeutics
In this randomized, partially-blind study ( clinicaltrials.gov ; NCT00541970), the licensed formulation of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine (20 μg each of HPV-16/18 antigens) was found highly immunogenic up to 4 y after f